Company: LIDRW
Filing Date: 2025-01-16
Form Type: S-1
Source: 0000947871-25-000056
Chunk: 15

Company: AEye, Inc.
Filing Date: 2025-01-16
Form: S-1
Chunk 15
---
94588.

| 12 |

THE OFFERING

| Shares of Common Stock offered by the Selling Stockholders | Up to 5,353,710 shares of the Common Stock, which                                                                                                                                                                                                                                                                                               
 consist of:                                                                                                                                                                                                                                                                                                                                     
 (i) 330,823 shares of Common Stock constituting the                                                                                                                                                                                                                                                                                             
 Dowslake Shares;                                                                                                                                                                                                                                                                                                                                
 (ii) up to 1,319,316 shares of Common Stock issued                                                                                                                                                                                                                                                                                              
 or issuable pursuant to the terms of the Dowslake Note;                                                                                                                                                                                                                                                                                         
 (iii) up to 2,495,676 shares of Common Stock issuable                                                                                                                                                                                                                                                                                           
 pursuant to the terms of the Convertible Note; and                                                                                                                                                                                                                                                                                              
 (iv) up to 1,207,895 shares of Common Stock issuable                                                                                                                                                                                                                                                                                            
 upon exercise of the Warrant.                                                                                                                                                                                                                                                                                                                   |
| Shares of Common Stock outstanding prior to this offering  | 15,848,161 shares of our Common Stock outstanding on January 14, 2025.                                                                                                                                                                                                                                                                          |
| Use of proceeds                                            | We are not selling any shares of Common Stock under this prospectus and will not receive any of the proceeds from the sale of shares of Common Stock by the Selling Stockholders. We will receive any proceeds from the cash exercise of the Warrant (if any), but not from the sale of the shares of Common Stock issuable upon such exercise. |
| Risk factors                                               | Investing in our Common Stock involves a high degree of risk. You should carefully read the “Risk Factors” beginning on page 14 and the other information included or incorporated by reference in this prospectus for a discussion of factors you should consider carefully before deciding to invest in our Common Stock.                     |
| Nasdaq symbol for our Common Stock                         | “LIDR”                                                                                                                                                                                                                                                                                                                                          |

| 13 |

<div align='center'>RISK FACTORS</div>

An investment in the Common Stock involves
a high degree of risk. Before you decide to invest in shares of Common Stock, you should consider carefully all of the information in
this prospectus and the documents incorporated by reference herein and, in particular, the risks described below and the Risk Factors
included in any prospectus supplement or amendment, our Annual Report on Form 10-K for the year ended December 31, 2023, and any subsequently
filed Quarterly Reports on Form 10-Q and our other filings with the SEC that are incorporated by reference into this prospectus. The risks
described in this